Theme Issue: Update on the role of the fibrinolysis/ plasminogen activation system in a cellular context

• References

• 1 Reuning U, Magdolen V, Wilhelm O. et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998; 13: 893-906.
• 2 Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6 (04) Suppl 3-26.
• 3 Schmitt M, Harbeck N, Thomssen C, Wilhelm O. et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285-96.
• 4 Stephens RW, Brünner N, Jänicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99-111.
• 5 Blasi F. Proteolysis, cell adhesion, chemo-taxis, and invasiveness are regulated by the u-PA-uPAR-PAI-1 system. Thromb Haemost 1999; 82: 298-304.
• 6 Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.
• 7 Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-7.
• 8 Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82: 259-270.
• 9 Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001; 86: 124-9.
• 10 Chapman HA, Wei Y, Simon DI, Waltz DA. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 1999; 82: 291-7.
• 11 Rosenberg S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective.Curr Top Med Chem. 2003 in press
• 12 Southan C. Assessing the protease and protease inhibitor content of the human genome. J Pept Sci 2000; 6: 453-8.
• 13 Deadman JJ. Proteinase inhibitors and activators. Strategic targets for therapeutic intervention. J Pept Sci 2000; 6: 421-31.
• 14 John L, Fawziah M, Ensom MHH. Role of therapeutic drug monitoring for protease inhibitors. Ann Pharmacotherapy 2001; 35: 745-54.
• 15 Zacharski LR, Ornstein DL, Gabazza EC, D’Alessandro-Gabazza CN, Brugarolas A, Schneider J. Treatment of malignancy by activation of the plasminogen system. Sem Thromb Hemost 2001; 28: 5-17.
• 16 Dunbar SD, Ornstein DL, Zacharski LR. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Exp Opin Invest Drugs 2000; 9: 2085-92.
• 17 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
• 18 Pintucci G, Bikfalvi A, Klein S, Rifkin DB. Angiogenesis and the fibrinolytic system. Semin Thromb Hemost 1996; 22: 517-24.
• 19 Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin Thromb Haemost 1996; 22: 525-42.
• 20 Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998; 91: 255-85.
• 21 Bajou K, Noel A, Gerard RD. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-8.
• 22 Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507-11.
• 23 Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 1998; 91: 2005-9.
• 24 Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62: 6966-72.
• 25 Degen JL. Genetic interactions between the coagulation and fibrinolytic systems. Thromb Haemost 2001; 86: 130-7.
• 26 Degen JL, Drew AF, Palumbo JS. et al. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann N Y Acad Sci 2001; 936: 276-90.
• 27 Romer J, Bugge TH, Pyke C. et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2: 287-92.
• 28 Kwaan HC. Modulation of tumor matrix by components of the plasminogen-plasmin system. In: Adany R, ed. Tumor Matrix Biology. Boca Raton, FL: CRC Press; 1995: 215-34.
• 29 Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillières Clin Haematol 1995; 8: 277-90.
• 30 Wilhelm O, Hafter R, Henschen A, Schmitt M, Graeff H. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 1990; 75: 1673-8.
• 31 Wilhelm O, Hafter R, Coppenrath E. et al. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res 1988; 48: 3507-14.
• 32 Kim J, Hajjar KA. Annexin II: a plasmino-gen-plasminogen activator co-receptor. Front Biosci 2002; 7: d341-88.
• 33 Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Hemost 1996; 22: 459-78.
• 34 Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002; 3: 196-200.
• 35 Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002; 26: 767-71.
• 36 Duffy MJ, Maguire TM, McDermott EW, O’Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999; 71: 130-5.
• 37 Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 20 (57) 25-40.
• 38 Look MP, van Putten WL, Duffy MJ. et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
• 39 Papadopoulou S, Scorilas A, Yotis J. et al. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol 2002; 23: 170-8.
• 40 Heiss MM, Simon EH, Beyer BC. et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002; 20: 2005-16.
• 41 Schmalfeldt B, Prechtel D, Härting K. et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001; 7: 2396-404.
• 42 Jänicke F, Prechtl A, Thomssen C. et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
• 43 Harbeck N, Kates RE, Look MP. et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002; 62: 4617-22.
• 44 Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2000; 20: 1000-7.
• 45 Preissner KT, Kanse SM, Chavakis T, May AE. The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: implications for cardiovascular function. Basic Res Cardiol 1999; 94: 315-21.
• 46 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
• 47 Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 1998; 4: 279-84.
• 48 Magdolen V, Arroyo de Prada N, Sperl S. et al. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol 2000; 477: 331-41.
• 49 Benraad TJ, Geurts-Moespot J, Grondahl-Hansen J. et al. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer 1996; 32A: 1371-81.